P3 Health Partners Inc. (PIII) Stock Forecast
PIII analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 2 analysts
- Price target
- $18.00 average of analyst targets
- Upside to target
- +334.8% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-7.40
- 52-week range
- $1.52 – $16.47
PIII analyst ratings
2 analystsNumber of analysts at each rating.
PIII price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PIII earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$7.40 | −$7.40 | −$7.40 | −$9.67 | +23.5% | 1 |
| Current fiscal year (2026) | −$14.84 | −$14.84 | −$14.84 | −$45.26 | +67.2% | 1 |
| Next fiscal year (2027) | −$13.88 | −$13.88 | −$13.88 | −$14.84 | +6.5% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PIII revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $385.1M | $385.0M | $385.3M | +11.6% | 2 |
| Current fiscal year (2026) | $1.55B | $1.54B | $1.56B | +6.3% | 2 |
| Next fiscal year (2027) | $1.70B | $1.60B | $1.79B | +9.4% | 2 |
PIII EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PIII revenue: reported and forecast
PIII EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$2.77 | −$2.77 | −$7.40 | −$7.40 | −$7.40 | +167.6% | 0 up · 1 down |
| Current fiscal year (2026) | −$8.45 | −$8.45 | −$14.84 | −$14.84 | −$14.84 | +75.7% | 0 up · 1 down |
| Next fiscal year (2027) | −$3.00 | −$3.00 | −$10.60 | −$13.88 | −$13.88 | +363.4% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PIII earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PIII beat in 4 of 12.
What analysts expect from PIII
2 analysts cover P3 Health Partners; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $18.00, 334.8% above the latest close of $4.14. Analysts expect earnings of −$14.84 per share for 2026, +67.2% from a year earlier. For 2027 the average estimate is −$13.88 per share on revenue of $1.7 billion. P3 Health Partners beat the EPS estimate in 4 of the last 12 quarters.
Related: PIII income statement, PIII key metrics, PIII chart. See the PIII stock overview for the latest quote and news.
PIII forecast FAQ
What is P3 Health Partners's price target?
The average analyst price target for P3 Health Partners is $18.00, 334.8% above the latest close of $4.14.
Is P3 Health Partners a buy, hold or sell?
Of 2 analysts covering P3 Health Partners, 1 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is P3 Health Partners's EPS forecast?
Analysts forecast −$14.84 per share for 2026 (range −$14.84 to −$14.84); for 2027 the estimate is −$13.88.
What is P3 Health Partners's revenue forecast?
The average revenue estimate for 2026 is $1.6 billion, growth of 6.3%; for 2027 it is $1.7 billion.
When does P3 Health Partners report earnings?
P3 Health Partners is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes; the EPS estimate is $-7.40.
Does P3 Health Partners usually beat earnings estimates?
P3 Health Partners reported EPS at or above the analyst estimate in 4 of the last 12 quarters.